Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar i disorder

PharmacoEconomics

Volumn 28, Issue 9, 2010, Pages 751-764

  Woodward, Tatia Chay ^a   Tafesse, Eskinder ^b   Quon, Peter ^a   Lazarus, Arthur ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

antipsychotics, therapeutic use; aripiprazole, therapeutic use; bipolar i disorders, treatment; cost utility; lamotrigine, therapeutic use; lithium, therapeutic use; olanzapine, therapeutic use; quetiapine, therapeutic use; valproate semisodium, therapeutic use

Indexed keywords

ARIPIPRAZOLE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM;

ABSENTEEISM; ARTICLE; BIPOLAR I DISORDER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; HOSPITALIZATION COST; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MANIA; MEDICAL FEE; MEDICAL LITERATURE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUICIDE; SUSTAINED DRUG RELEASE;

ABSENTEEISM; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEES, PHARMACEUTICAL; HEALTH CARE COSTS; HOSPITAL CHARGES; HUMANS; LITHIUM COMPOUNDS; MARKOV CHAINS; MODELS, ECONOMIC; OFFICE VISITS; PIPERAZINES; QUALITY-ADJUSTED LIFE YEARS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TABLETS; TREATMENT OUTCOME; TRIAZINES; UNITED STATES; VALPROIC ACID;

EID: 77956239748     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11538350-000000000-00000     Document Type: Article

References (32)

1. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 Apr; 159 (4 Suppl.): 1-50
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007 May; 64 (5): 543-552
3. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005; 23 (6): 583-594
4. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994 Jun; 31 (2): 91-96
5. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar dis-order. Pharmacoeconomics 2003; 21 (9): 601-622
6. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 19 Pharmacoeconomics 2001; 19 (5 Pt 1): 483-495
7. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 19 Soc Psychiatry Psychiatr Epidemiol 1995 Aug; 30 (5): 213-219
8. McIntyre RS, Woldeyohannes HO, Yasgur BS, et al. Maintenance treatment in bipolar disorder: a focus on ar-ipiprazole. Expert Rev Neurother 2007 Aug; 7 (8): 919-925
9. Suppes T, Vieta E, Liu S, et al., Trial 127 investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009 Apr; 166 (4): 476-488
10. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International Trial 126). J Affect Disord 2008 Aug; 109 (3): 251-263
11. Figueroa C, Brecher M, Hamer-Maansson JE, et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33 (2): 199-204
12. Calvert NW, Burch SP, Fu AZ, et al. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 2006 May; 12 (4): 322-330
13. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 Apr; 60 (4): 392-400
14. Prescribing information: Seroquel XR. Wilmington (DE): AstraZeneca Pharmaceuticals LP [online]. Available from URL http://wwastrazeneca-us.com/pi/ seroquelxr.pdf [Accessed 2009 Oct 1]
15. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, pla-cebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006 Feb; 163 (2): 247-256
16. Keck Jr PE, Calabrese JR, McQuade RD, et al. A random-ized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006 Apr; 67 (4): 626-637
17. US Department of Health and Human Services; Centers for Disease Control and Prevention. Deaths: final data for 20 Natl Vital Stat Rep 2007 Aug 21; 55 (19) [online]. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr55/ nvsr55-pdf [Accessed 2010 Jun 3]
18. Simon GE, Hunkeler E, Fireman B, et al. Risk of suicide attempt and suicide death in patients treated for bipolar disorder. Bipolar Disord 2007 Aug; 9 (5): 526-530
19. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007; 25 (1): 3-6
20. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003 Sep; 64 (9): 1013-1024
21. Brazier J, Roberts J, Deverill M. The estimation of a pref-erence-based measure of health from the SF-J Health Econ 2002 Mar; 21 (2): 271-292
22. Red Book™ for Windows®. Version 611 Montvale (NJ): Thomson Reuters, 2009
23. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. Am J Psychiatry 2006 Sep; 163 (9): 1561-1568
24. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000 Jul; 20 (3): 332-342
25. Fleurence RL, Chatterton ML, Dixon JM, et al. Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review. Prim Care Companion J Clin Psychiatry 2007; 9 (6): 419-428
26. Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 2007; 11 (39): iii-iv, ix-206
27. McKendrick J, Cerri KH, Lloyd A, et al. Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom. J Psychopharmacol 2007 Aug; 21 (6): 588-596
28. Kupfer DJ, Frank E, Grochocinski VJ, et al. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 2000; 12: 110-114
29. Kessing LV, Munk-Jorgensen P. Does type of first contact in depressive and bipolar disorders predict subsequent hospitalisation and risk of suicide? J Affect Disord 2004 Nov 15; 83 (1): 65-71
30. Gonzalez-Pinto AM, Dardennes R, de Zelicourt M, et al. In-patient care costs of patients with bipolar I disorder: a comparison between two European centers. J Affect Dis-ord 2010 Nov; 121 (1-2): 152-155
31. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998 Feb; 48 (1): 25-36
32. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005; 66 Suppl. 3: 28-36